Kido Takumi, Kyono Yuki, Suga Shutaro, Nakasone Ruka, Abe Shinya, Ashina Mariko, Matsumoto Hisayuki, Tanimura Kenji, Nozu Kandai, Fujioka Kazumichi
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Department of Clinical Laboratory, Kobe University Hospital, Kobe 650-0017, Japan.
J Clin Med. 2021 Dec 14;10(24):5864. doi: 10.3390/jcm10245864.
For symptomatic congenital cytomegalovirus infections (CCMVI), the usefulness of changes in viral load during valganciclovir (VGCV) treatment for the prediction of hearing dysfunction (HD) is unclear. To determine the utility of viral load change in the whole blood or urine for the prediction of HD, we performed a retrospective study to compare viral load changes during VGCV treatment between CCMVI infants with ( = 12) or without ( = 8) HD at six months of corrected age, whose blood and urine viral loads were measured continuously for eight weeks from April 2009 to December 2019. There was no significant difference in the changes in both the blood and urine viral loads after the initiation of VGCV treatment between CCMVI infants between the groups. Moreover, this negative result was maintained in the analysis for each six weeks or six months treatment period. In conclusion, the change in viral load during antiviral therapy is not useful for the prediction of HD at six months of corrected age in symptomatic CCMVI.
对于有症状的先天性巨细胞病毒感染(CCMVI),缬更昔洛韦(VGCV)治疗期间病毒载量变化对听力功能障碍(HD)预测的有用性尚不清楚。为了确定全血或尿液中病毒载量变化对HD预测的效用,我们进行了一项回顾性研究,比较了校正年龄6个月时患有(n = 12)或未患有(n = 8)HD的CCMVI婴儿在VGCV治疗期间的病毒载量变化,这些婴儿从2009年4月至2019年12月连续8周测量血液和尿液病毒载量。两组之间CCMVI婴儿在开始VGCV治疗后血液和尿液病毒载量的变化没有显著差异。此外,在每六周或六个月治疗期的分析中,这一阴性结果保持不变。总之,抗病毒治疗期间病毒载量的变化对于有症状的CCMVI校正年龄6个月时HD的预测没有用处。